The effects of tongxinluo capsule on platelet activity and vascular endothelium function as well as prognosis at different stage in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Chen, Zhangqiang; Liu, Hong; Wang, Hong; Yin, Qin

doi:10.1136/heartjnl-2011-300867.447

Cited by 9 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A piece of research was conducted on patients who were diagnosed with acute coronary syndrome and received percutaneous coronary intervention. After TMP treatment, the level of CD63, an indicator of platelet activation, decreased significantly [ 36 ]. TMP might have an effect on inhibition of platelet release, although no experimental study is conducted to verify the role of TMP in platelet release reaction.…”

Section: Medicinal Use Of Tmpmentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective

Zhao

Liu

Chen

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Tetramethylpyrazine, a natural compound from Ligusticum wallichii (Chuan Xiong), has been extensively used in China for cardiovascular and cerebrovascular diseases for about 40 years. Because of its effectiveness in multisystems, especially in cardiovascular, its pharmacological action, clinical application, and the structural modification have attracted broad attention. In this paper its mechanisms of action, the clinical status, and synthetic derivatives will be reviewed briefly.

show abstract

Section: Medicinal Use Of Tmpmentioning

confidence: 99%

“…The injection solution of TMP has been broadly used especially in China to treat ischemic stroke [ 81 ], coronary heart disease [ 36 ], diabetic nephropathy [ 82 ], and knee osteoarthritis [ 83 ]. Large amount of research is about the efficacy of TMP injection.…”

Section: Current Status Of Therapeutic Uses Of Tmpmentioning

confidence: 99%

Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective

Zhao

Liu

Chen

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Hence, it might improve vascular endothelial function in AMI patients [ 67 ]. Chen et al [ 68 ] explored the effect of TMP on platelet activation and vascular endothelial function after PCI in patients with ACS. The results showed that TMP decreases CD62p, CD63, GPIIb/IIIa, vWF, and ET-1 levels.…”

Section: Tmp and Cardiovascular Diseasesmentioning

confidence: 99%

Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated fromRhizoma Chuanxiong): Roles and Mechanisms

Guo

Liu

Shi

2016

BioMed Research International

View full text Add to dashboard Cite

Tetramethylpyrazine (TMP), a pharmacologically active component isolated from the rhizome of the Chinese herb Rhizoma Chuanxiong (Chuanxiong), has been clinically used in China and Southeast Asian countries for the prevention and treatment of cardiovascular diseases (CVDs) for about fifty years. The pharmacological effects of TMP on the cardiovascular system have attracted great interest. Emerging experimental studies and clinical trials have demonstrated that TMP prevents atherosclerosis as well as ischemia-reperfusion injury. The cardioprotective effects of TMP are mainly related to its antioxidant, anti-inflammatory, or calcium-homeostasis effects. This review focuses on the roles and mechanisms of action of TMP in the cardiovascular system and provides a novel perspective on TMP's clinical use.

show abstract

“…The cardioprotective benefits of TXL against MI were closely related to the inhibition of apoptosis and promotion of autophagy in rat hearts after AMI by activating AMPK signaling pathway (Li Q. et al, 2017 ). TXL also exhibited anti-platelet aggregation effects (Chen et al, 2016 ). TXL may probably exhibit a specific advantage in the prevention and treatment of myocardial fibrosis via mediating the expressions of TGF-beta1, Smad3, and Smad7 in diabetic rats (Wang X. et al, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Chen

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Chinese patent medicine Tongxinluo capsule (TXL) is commonly used for cardio-cerebrovascular diseases. Previous research had demonstrated that TXL exhibited great clinical effects on the treatment of acute myocardial infarction (AMI), however there is a lack of systematic review. The purpose of this study was to evaluate the potential effectiveness and safety of TXL for secondary prevention in patients with AMI.Method: We searched 6 databases to identify relevant randomized controlled trials (RCTs) from inceptions to December 30, 2017. Two review authors independently assessed the methodological quality and analyzed data by the RevMan 5.3 software. The publication bias was assessed through funnel plot and Begg's test. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used for evaluating the quality of evidence.Results: We included 19 RCTs in this review and performed a meta-analysis based on 16 studies. There were statistical differences of TXL treatment group in reducing primary cardiovascular events (cardiac death [RR = 0.27, 95%CI: 0.08~0.95, I2 = 0%], recurrent myocardial reinfarction [RR = 0.38, 95%CI: 0.20~0.74, I2 = 0%], arrhythmia [RR = 0.44, 95%CI: 0.30~0.66, I2 = 0%], recurrent angina pectoris [RR = 0.34, 95%CI: 0.17~0.69, I2 = 0%]). TXL could improve cardiac function (LVEF [MD = 4.10, 95%CI: 3.95~4.25, I2 = 0%]), regulate blood lipid TC [MD = −0.66, 95%CI: −0.94 ~ −0.37, I2 = 74%], TG [MD = −0.38, 95%CI: −0.62 ~ −0.14, I2 = 70%], LDL-C[−0.40, 95%CI: −0.65 ~ −0.16, I2 = 88%), decrease the level of hs-CRP (4-week: MD = −0.78, 95%CI: −0.97 ~ −0.60, I2 = 20%; Over 4-week: MD = −1.36, 95%CI: −1.55 ~ −1.17, I2 = 20%). However, TXL has little effects on revascularization [RR = 0.45, 95%CI: 0.13~1.56, I2 = 0%], recurrent heart failure (RR = 0.83, 95%CI: 0.27~2.57, I2 = 0%), and HDL-C (MD = 0.14, 95%CI: 0.00 ~0.29, I2 = 73%). Furthermore, TXL treatment group was more prone to suffer gastrointestinal discomfort.Conclusion: Chinese patent medicine TXL seemed beneficial for secondary prevention after AMI. This potential benefit needs to be further assessed through more rigorous RCTs.Systematic review registration number in the PROSPERO register: CRD42017068417.

show abstract

The effects of tongxinluo capsule on platelet activity and vascular endothelium function as well as prognosis at different stage in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Cited by 9 publications

References 0 publications

Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective

Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective

Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated fromRhizoma Chuanxiong): Roles and Mechanisms

Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About